Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. (28th December 2021)

• Record Type: Journal Article
• Authors: Zhu, Yefei; Lin, Shuangxiang; Wang, Yueping; Shen, Bingxiao; Lin, Ling; Wang, Liangxing; He, Susu
• Other Names: Koundal Deepika Academic Editor.
• Is Part Of: Computational and mathematical methods in medicine. Volume 2021(2021)
• Publication Date: 2021-12-28
• Subjects: Medicine -- Computer simulation -- Periodicals; Medicine -- Mathematical models -- Periodicals; 610.11
• DOI: 10.1155/2021/3273347
• Languages: English
• ISSNs: 1748-670X

Abstract

Abstract : PD-L1 is one of the current biomarkers for immune checkpoint inhibitor (ICI) therapy in patients with non-small-cell lung cancer. However, the expression of PD-L1 in the real world and its related influencing factors remain unclear. We want to observe the expression of PD-L1 in the real world and study the related influencing factors through the collection and analysis of clinical data. R software (version 4.0) was used to perform data analysis and the "corplot" package for correlation analysis. A total of 296 individuals (mean [SD] age, 67 [9] years; 23%female) were assessed. According to the expression amount of PD-L1, the cohort was divided into low nonexpression group (PD ‐ L 1 < 1 %, 26.7%), low-expression group (1 % ≤ PD ‐ L 1 < 50 %, 49.3%), and high-expression group (PD ‐ L 1 ≥ 50 %, 23.5%). Age, gender, underlying diseases, smoking status, and PD-L1 expression level were not statistically significant. We found that the expression of PD-L1 was correlated with serum albumin (P < 0.05 ) and pathological type (P < 0.05 ) and had a negative correlation with EGFR mutation but did not correlate with gender, age, smoking status, combined with underlying diseases, tumor stage, whether it was initially treated or not, sampling site, specimen type, specimen storage time, R-IFN, CD4, CD8, NLR, CRP, and LDH. The present findings indicated that serum albumin, pathological type, and EGFR mutations are associated with PD-L1 expression in patients with NSCLC, which may provide a new basis for individualized immunotherapy and need further study to confirm. The results of this study help to further reveal the actual expression of PD-L1 in non-small-cell lung cancer patients with real events.